These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31767829)

  • 1. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
    Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
    Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp.
    Zhou Q; Wen J; Xu F; Yue J; Zhang Y; Su J; Liu Y
    Technol Cancer Res Treat; 2024; 23():15330338241252605. PubMed ID: 38759699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
    Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
    Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
    Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis.
    Suzuki K; Tsukada N; Nishimura N; Nagata Y; Okazuka K; Mishima Y; Yokoyama M; Nishiwaki K; Ishida T; Yano S; Terui Y; Suzuki K
    Int J Hematol; 2020 Jan; 111(1):103-111. PubMed ID: 31673952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
    Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
    N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
    Cook J; Johnson I; Higgins A; Sidana S; Warsame R; Gonsalves W; Gertz MA; Buadi F; Lacy M; Kapoor P; Dispenzieri A; Kourelis T; Dingli D; Fonder A; Hayman S; Hobbs M; Hwa YL; Kyle R; Leung N; Go R; Rajkumar VS; Kumar S
    Am J Hematol; 2021 Mar; 96(3):330-337. PubMed ID: 33326116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
    D'Agostino M; Rota-Scalabrini D; Belotti A; Bertamini L; Arigoni M; De Sabbata G; Pietrantuono G; Pascarella A; Tosi P; Pisani F; Pescosta N; Ruggeri M; Rogers J; Olivero M; Garzia M; Galieni P; Annibali O; Monaco F; Liberati AM; Palmieri S; Stefanoni P; Zamagni E; Bruno B; Calogero RA; Boccadoro M; Musto P; Gay F
    Blood Cancer J; 2024 Jun; 14(1):94. PubMed ID: 38849344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
    Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
    Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
    Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
    Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
    Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
    J Clin Oncol; 2020 Jun; 38(17):1928-1937. PubMed ID: 32298201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
    Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
    Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
    PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
    Neupane K; Fortuna GG; Dahal R; Schmidt T; Fonseca R; Chakraborty R; Koehn KA; Mohan M; Mian H; Costa LJ; Sborov D; Mohyuddin GR
    Blood Cancer J; 2024 Jan; 14(1):20. PubMed ID: 38272897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
    Shah GL; Landau H; Londono D; Devlin SM; Kosuri S; Lesokhin AM; Lendvai N; Hassoun H; Chung DJ; Koehne G; Jhanwar SC; Landgren O; Levine R; Giralt SA
    Leuk Lymphoma; 2017 Aug; 58(8):1823-1831. PubMed ID: 28078910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
    Richardson PG; Schjesvold F; Weisel K; Moreau P; Anderson LD; White D; Rodriguez-Otero P; Sonneveld P; Engelhardt M; Jenner M; Corso A; Dürig J; Pavic M; Salomo M; Beksac M; Oriol A; Lindsay J; Liberati AM; Galli M; Robak P; Larocca A; Yagci M; Vural F; Kanate AS; Jiang R; Grote L; Peluso T; Dimopoulos M
    Eur J Haematol; 2022 Jan; 108(1):73-83. PubMed ID: 34496096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.